Combining two ambitious cancer research teams to form a united front to help people with cancer
It’s sometimes said that the whole is greater than the sum of its parts. That’s why we teamed up with Merck in 2018 to work together to advance research and improve the lives of those impacted by cancer.
“Combining Merck’s leadership in immuno-oncology with Eisai’s strengths in small molecules allows us to advance a combination approach that has the potential to help more people living with challenging cancers,” said Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, Merck Research Laboratories.
“There is still an unmet need for many patients with cancer. These patients and their families are in need of more treatment options, and this remains at the forefront of our collaborative efforts.”
Dr. Takashi Owa, Vice President, Chief Medicine Creation and Chief Discovery Officer, Oncology Business Group, Eisai
Together, we are striving to drive cancer science forward, and this shared vision has led to multiple clinical trials investigating the companies’ combination treatment option in more than various tumor types.
Through this comprehensive approach, we have been expanding the joint clinical program to help as many cancer patients as possible.
Why did you decide to go into oncology research?
“My decision was very personal,” says Dr. Owa. “At the age of 6, my grandmother passed away from gastric cancer. I couldn’t fully process what had happened to her at that young age. It wasn’t until I entered junior high school that I began to understand the toll cancer had taken on her, which motivated me to learn about cancer and find my passion in cancer research.”
Dr. Lubiniecki’s experience was also very personal.
“Watching my mother recover from breast cancer while I was in high school exposed me to the challenges patients face when battling cancer. These experiences inspired me to ultimately pursue oncology,” explains Lubiniecki. “Oncology clinical research offers an opportunity to impact the practice of medicine greatly.”
Looking to the future
“I’m proud of what we have been able to accomplish together in our pursuit to investigate additional options for patients across a broad range of cancer types through our robust clinical development program,” says Dr. Lubiniecki.
Dr. Owa is optimistic about the progress the two teams have made together. “We have already seen encouraging anti-tumor activity in several difficult-to-treat cancers, which has led to multiple milestones to date,” he says. “As we continue to enhance our knowledge and scientific evidence through our ongoing clinical research efforts, together, we aim to give patients and their families hope.”
Dr. Lubiniecki believes that collaborations are important to continuing to advance cancer research and improve the outcomes of people with cancer.
“A collaborative approach is key to advancing science and making strides in drug discovery and development.”
Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, Merck Research Laboratories.
“Working with others driven by the same patient-centric goals can yield innovations and is imperative to continued progress in improving patient care. I’m thrilled to be a part of this collaboration as we continue to advance and expand the clinical trial program.”
US4293